New research suggests that people who discontinue blockbuster GLP-1 drugs like semaglutide or tirzepatide can put back on reduced body mass much more quickly than those who stop conventional lifestyle plans.
Research printed in a major medical journal points out that while obese people can lose about a fifth of their total mass while undergoing treatment, the weight returns at an estimated rate of 0.8 kg per month after stopping.
"Users using these treatments need to be cognizant of the danger of fast rebound weight gain when the treatment concludes," warns researcher Dr. Susan Jebb.
Such speed of recovery means a return to original mass within about a year and a half.
Weighing Treatments
The research, which looked at dozens of studies involving thousands of participants, compared the effects of GLP-1 agonists with other pills.
The team emphasize that individuals who lose weight through diet and exercise generally experience a slower weight regain—perhaps 100 grams monthly—once they finish.
Understanding the Quick Rebound
Doctors suggest the way of the jabs explains the heightened regain.
These medications imitate a body's own chemical called glucagon-like peptide-1, which helps regulate feelings of fullness.
"Long-term administration of the hormone levels far above than the body's typical production may cause the system to generate a reduced amount of its endogenous GLP-1, and may also lessen responsiveness to its effects," noted Dr. Adam Collins, a dietetics researcher.
"Withdrawal of this hormone supplement means appetite is unsuppressed, making overeating far more likely."
A Lifelong Condition?
The NHS advise the injections for individuals with obesity-related medical conditions, accompanied by prescribed diet and exercise modifications.
Professionals contend that, given the high risk of weight regain, the therapy might need to be ongoing.
This opinion is supported by drug manufacturers, who state that the results "underscore the persistent nature of obesity," akin to managing diseases like high blood pressure.
Patient Experiences
Individuals who have stopped the medication explain a intense return of hunger.
"It felt as if something activating and you become ravenous," said a patient.
This challenge is worsened if patients have not developed lasting lifestyle or habit changes during treatment.
Growing Use
Survey data indicate that a significant number of adults in the UK have tried weight-loss jabs in the past year, with demand remaining high.
- Use is more common among females compared to men.
- The middle-aged age group shows the highest level of interest.
- A large proportion access the drugs through private prescriptions rather than public health services.
Ultimately, experts stress that while these medications are effective tools for shedding pounds, they are not a permanent solution and long-term success relies on integrated behavioural support.
